Next Wave of Immune Engagers in Hematological Malignancies | Partnering Meetings with Johnson and Johnson Innovation
Opens Sep 7 2021 02:00 PM (GMT)
Deadline Oct 15 2021 09:59 PM (GMT)
Description

At Johnson & Johnson Innovation we are seeking to nurture new connections and collaborations to create transformational curative regimens and push the boundaries in immune cell engaging therapeutics.

We are working towards comprehensive regimens, synergistic combinations and novel targets, all aimed at intercepting disease and moving towards cures in hematologic malignancies such as:

  1. B-cell malignancies
  2. Multiple myeloma
  3. Myeloid malignancies

We are seeking to connect with entrepreneurs, biotechs and academic researchers who are part of the next wave of science and innovation, including:

  1. Discovery of novel tumor specific lineage antigens
  2. Redirection of immune effector cells with enhanced efficacy and safety
  3. Allogenic “off the shelf” cell therapy platforms

If you are active in the areas of interest listed above, we invite you to request a 1:1 meeting with the Johnson & Johnson Innovation team by EOD 15 October, 2021.

Application Process

  1. Log in or create an account on Survey Monkey Apply
  2. Fill in the application form and upload non-confidential information (you can save and return)
  3. Submit by end of day 15 October
  4. Selected organizations, academic groups or companies will receive an invitation
  5. Confirm attendance of your one-to-one meeting within 2 days

If you have any questions please contact Cosmin Popa.

Next Wave of Immune Engagers in Hematological Malignancies | Partnering Meetings with Johnson and Johnson Innovation


At Johnson & Johnson Innovation we are seeking to nurture new connections and collaborations to create transformational curative regimens and push the boundaries in immune cell engaging therapeutics.

We are working towards comprehensive regimens, synergistic combinations and novel targets, all aimed at intercepting disease and moving towards cures in hematologic malignancies such as:

  1. B-cell malignancies
  2. Multiple myeloma
  3. Myeloid malignancies

We are seeking to connect with entrepreneurs, biotechs and academic researchers who are part of the next wave of science and innovation, including:

  1. Discovery of novel tumor specific lineage antigens
  2. Redirection of immune effector cells with enhanced efficacy and safety
  3. Allogenic “off the shelf” cell therapy platforms

If you are active in the areas of interest listed above, we invite you to request a 1:1 meeting with the Johnson & Johnson Innovation team by EOD 15 October, 2021.

Application Process

  1. Log in or create an account on Survey Monkey Apply
  2. Fill in the application form and upload non-confidential information (you can save and return)
  3. Submit by end of day 15 October
  4. Selected organizations, academic groups or companies will receive an invitation
  5. Confirm attendance of your one-to-one meeting within 2 days

If you have any questions please contact Cosmin Popa.

Opens
Sep 7 2021 02:00 PM (GMT)
Deadline
Oct 15 2021 09:59 PM (GMT)